Figure 4

ALA treatment decreased the TGF-β,α-SMA, and TIMP-2 expression and increased cardiac active- and pro- MMP-2 levels. The protein expression of TGF-β (A), α-SMA (B), and TIMP-2 (C) were determined by Western blot with specific antibodies as indicated, β-Actin was used as loading control. Cardiac active- and pro- MMP-2 (D/E) levels were assayed by zymogram. Representative image, bar graph, density analysis results from 8 hearts per group. Data represent mean ± standard deviation. *p < 0.05 vs Control group, #p < 0.05 vs. STZ group.